Lara, Primo N. Jr
Villanueva, Luis
Ibanez, Carolina
Erman, Mustafa
Lee, Jae Lyun
Heinrich, Daniel
Lipatov, Oleg Nikolaevich
Gedye, Craig
Gokmen, Erhan
Acevedo, Alejandro
Semenov, Andrey
Park, Se Hoon
Gafanov, Rustem Airatovich
Kose, Fatih
Jones, Mark
Du, Xiaoqi
Munteanu, Mihaela
Perini, Rodolfo
Choueiri, Toni K.
Motzer, Robert J.
Funding for this research was provided by:
Merck Sharp & Dohme LLC
Article History
Received: 5 August 2022
Accepted: 16 May 2023
First Online: 25 July 2024
Declarations
:
: Independent institutional review boards or ethics committees reviewed and approved the protocol and applicable amendments for each institution. All patients provided written informed consent. Full details of the names of IRB committees and participating sites are included in the Supplementary Materials. The study was conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki.
: Not applicable.
: PNL: Received research funding to his institution during the conduct of the study from Incyte.LV: No conflicts to disclose.CI: No conflicts to disclose.ME: Received personal fees in the form of consulting and/or lectures from Pfizer, Merck Sharp & Dohme, Roche, Astellas, Janssen Novartis, Gen Ilac, Nobel Ilac, Bristol Myers Squibb, Takeda, AstraZeneca, Deva Ilac, Abdi Ibrahim Ilac and personal fees in the form of investigator fees from Pfizer, Merck Sharp & Dohme, Roche, Janssen, Novartis, Bristol Myers Squibb, Beigene, AstraZeneca, Merck, Abbvie, and Eli Lilly.JLL: Received research funding outside the submitted work from Pfizer Korea, Ipsen Korea, Bristol Myers Squibb, Merck Sharp & Dohme, Merck, Eisai, Roche, AstraZeneca, Exelixis and SeaGen; received personal fees from Pfizer Korea, Ipsen Korea, Sanofi Aventis, Novartis Korea, Astellas Korea, Bristol Myers Squibb, Merck Sharp & Dohme, and AstraZeneca; is a member of advisory boards for Pfizer Korea, Ipsen Korea, Sanofi Aventis, Astellas Korea, Bristol Myers Squibb, Merck Sharp & Dohme, Merck, and Eisai; and has stock ownership of Myovant Science, Merck, Amgen, and Johnson & Johnson.DH: Received research funding from Merck Sharp & Dohme for conduct of the current study, received research funding outside the submitted work from Eisai and Bristol Myers Squibb, and received personal fees from Eisai, Ipsen, and Bristol Myers Squibb.ONL: No conflicts to disclose.CG: received personal fees recorded as paid to Dr Gedye but donated direct and complete to third-party NFP from Astellas, Janssen, AstraZeneca, Bristol Myers Squibb, Pfizer/EMD Serono, and Ipsen, and received travel support, but taken in lieu of taxpayer funded employment contract entitlement from Ipsen, Astellas, and Merck Sharp & Dohme.EG: No conflicts to disclose.AA: received research funding from Merck Sharp & Dohme for conduct of the current study.AS: Received research funding outside the submitted work from Astellas, Janssen, AstraZeneca, Merck Sharp & Dohme, and Hoffmann La-Roche.SHP: No conflicts to disclose.RAG: Received research funding from Merck Sharp & Dohme for conduct of the current study.FK: No conflicts to disclose.MJ: Employee and stockholder of Incyte Corporation, Wilmington, DE, USA.XD: Employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA at the time of the analysis.MM: Employee and stockholder of Incyte Corporation, Wilmington, DE, USA.RP: Employee of Merck Sharp & Dohme, LLC a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and a stockholder of Merck & Co., Inc.TKC: Has served on advisory boards, provided consultation, and received clinical trial grants from AstraZeneca, Bristol Myers Squibb, Exelixis, Pfizer, Janssen, Merck Sharp & Dohme, Eli Lilly, Eisai, Novartis, GlaxoSmithKline, Infinity, Surface Oncology, and EMD Serono; has stock ownership in Pionyr and Tempest; has patents pending and issues related to biomarkers of immuno-oncology; and sits on the NCCN kidney panel. He received royalties from Up-To-Date. He received fees for CME-accredited activities from Medscape, OncLive, and Research to Practice.RJM: Received research funding during the conduct of the study from Incyte, had a consultant/advisory role during the conduct of the study from Merck and Incyte, received research funding outside the submitted work to his institution from Pfizer, Novartis, Genentech, Roche, and Bristol Myers Squibb, and has a consultant/advisory role for Pfizer, Novartis, Exelixis, Genentech, Incyte, Eli Lilly, Roche, AstraZeneca, EMD Serono, and Aveo Pharmaceuticals.